China CAR T-Cell Therapy Market (2026-2031)
The China CAR T-Cell Therapy Market was valued at $0 Million in 2026 and projected to reach to $0 Million by 2031, representing a compound annual growth rate of . China's CAR T-cell therapy market remains underdeveloped with zero market activity projected through 2031, contrasting sharply with the global market's 13.7% CAGR.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
China CAR T-Cell Therapy Market Trends and Insights
- This absence of market activity in China reflects significant regulatory, infrastructural, and commercialization barriers that distinguish the country from global CAR T-cell therapy adoption trends.
- Despite the global market expanding at a 13.7% CAGR from 2026 to 2031, China remains outside this growth trajectory, suggesting fundamental challenges in market development and therapeutic accessibility. The lack of CAR T-cell therapy market presence in China during the 2026-2031 forecast period indicates that commercial availability and patient access remain severely limited or non-existent.
- China's healthcare system, while advancing rapidly in oncology treatments, has not yet established the necessary regulatory pathways, manufacturing infrastructure, or reimbursement mechanisms to support CAR T-cell therapy commercialization.
- This contrasts sharply with developed markets where CAR T-cell therapies have achieved significant clinical adoption and market penetration. Looking toward 2031, China's CAR T-cell therapy market outlook remains stagnant without intervention in regulatory frameworks, healthcare investment, or technology transfer agreements.
- The absence of market activity suggests that China may require substantial policy reforms and healthcare infrastructure development to participate in the global CAR T-cell therapy market expansion..
Key Market Statistics
- CAGR (2026-2031)
- Market Size, 2026 ~USD 0 Million
- Forecast, 2031 ~USD 0 Million
- Country China
China CAR T-Cell Therapy Market Overview
Zero Market Activity :
China's CAR T-cell therapy market shows no measurable market size in 2026, indicating absence of commercial availability and patient access despite global market expansion at 13.7% CAGR.
Regulatory Barriers :
Stringent Chinese regulatory frameworks and approval processes for advanced cell therapies create significant obstacles to market entry, delaying commercialization compared to Western markets.
Infrastructure Limitations :
Lack of specialized manufacturing facilities, cold chain logistics, and clinical infrastructure required for CAR T-cell therapy production and administration restricts market development in China.
Future Growth Potential :
Despite current market absence, China's substantial patient population, increasing healthcare investments, and emerging biotech capabilities position the market for potential future expansion post-2031.
China CAR T-Cell Therapy Market Dynamics
- This absence reflects complex regulatory requirements, limited manufacturing infrastructure, and restricted patient access to advanced immunotherapies.
- Chinese regulatory authorities maintain cautious approval standards for cell-based therapies, creating extended timelines for market entry. However, China's healthcare sector is undergoing rapid modernization with increased R&D investments in biotechnology.
- As regulatory frameworks evolve and domestic manufacturing capabilities strengthen, the market may transition from dormancy to growth in the post-2031 period.
- Strategic partnerships between international CAR T developers and Chinese institutions could accelerate commercialization timelines..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- China's CAR T-cell therapy market shows zero market size in 2026 with no projected growth through 2031, indicating complete market absence.
- Regulatory barriers and lack of manufacturing infrastructure prevent CAR T-cell therapy commercialization in China despite global market expansion.
- China's healthcare system has not established reimbursement mechanisms or clinical pathways necessary for CAR T-cell therapy adoption.
- Market development in China requires significant policy reform and healthcare infrastructure investment to align with global CAR T-cell therapy trends.
CAR T-Cell Therapy Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2026 |
| Fastest Growing Segment | CD19/20 (Target) |
| Forecast Period | 2026–2031 |
| Growth Rate | CAGR of 13.7% from 2026 to 2031 |
| Largest Segment | CD19 (Target) |
| Market Size Base Year (Billions) | ~USD 7.25 (2026) |
| Revenue Forecast (Billions) | ~USD 13.78 (2031) |
| Segments Covered | Product, Target, Indication |
China CAR T-Cell Therapy Market Report Segmentation
3 segment dimensions are covered across the global market.
By Product
- Abecma
- Breyanzi
- Carvykti
- Kymriah
- Other Products
- Tecartus
- Yescarta
By Target
- Bcma
- Cd19
- Cd19/20
- Cd7
- Other Targets
By Indication
- Acute Lymphoblastic Leukemia (All)
- B-Cell Lymphoma (Bcl)
- Multiple Myeloma
- Other Indications
CHINA: CAR T-CELL THERAPY MARKET, BY END USER, 2024–2031
| Segment | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 42 | 47.9 | 53.5 | 61.5 | 71.7 | 85.9 | 107.4 | 147.8 | 22.5 |
| LONG-TERM CARE FACILITIES | 2.5 | 2.9 | 3 | 3.3 | 3.7 | 4.2 | 4.9 | 6.3 | 15.7 |
| SPECIALTY CENTERS | 15.3 | 17.5 | 19.4 | 22.3 | 25.9 | 30.9 | 38.4 | 52.7 | 22.1 |
| TOTAL | 59.9 | 68.2 | 76 | 87.1 | 101.3 | 120.9 | 150.7 | 206.8 | 22.2 |
Target Audience
- Pharmaceutical & Biotech Companies : Assess China market entry feasibility, regulatory requirements, and commercialization timelines to develop long-term strategic plans for CAR T-cell therapy expansion in Asia Pacific.
- Healthcare Investors & PE Firms : Evaluate investment opportunities in Chinese biotech infrastructure, manufacturing capabilities, and partnerships that could enable future CAR T-cell therapy market development.
- Medical Device & Manufacturing Suppliers : Identify infrastructure gaps and manufacturing requirements to position products and services for anticipated market growth and facility development in China.
- Healthcare Policy & Regulatory Consultants : Understand current regulatory barriers and approval pathways to advise clients on compliance strategies and market readiness assessments for China operations.
- Hospital & Clinical Networks : Prepare for future CAR T-cell therapy availability by understanding current market status, infrastructure needs, and anticipated commercialization timelines for clinical readiness planning.
Key Companies in the China CAR T-Cell Therapy Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| JOHNSON & JOHNSON | United States | Public Company | Oncology and Immunology (Innovative Medicine),Neuroscience, Cardiovascular & Metabolism, Pulmonary Hypertension, Infectious Diseases,Surgery and Interventional (instrumentation, energy, stapling, wound closure, biosurgery, robotic and digital), |
| GILEAD SCIENCES, INC. | United States | Public Company | HIV portfolio (Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, Yeztugo),Liver disease and other antivirals (Epclusa, Livdelzi, Vemlidy, AmBisome),COVID-19 (Veklury), |
| BRISTOL-MYERS SQUIBB COMPANY | United States | Public Company | Eliquis (anticoagulation),Immuno-oncology (Opdivo, Yervoy, Opdualag, Opdivo Qvantig),Hematology (Revlimid, Pomalyst/Imnovid, Reblozyl, Abecma, Breyanzi), |
| NOVARTIS AG | Switzerland | Public Company | Oncology & Hematology (Kisqali, Tafinlar+Mekinist, Jakavi, Pluvicto, Lutathera, Scemblix, Fabhalta),Immunology & Neuroscience (Cosentyx, Xolair, Ilaris, neurology assets),Cardiovascular, Renal & Metabolic (Entresto, Leqvio, other CVRM), |
| AUTOLUS THERAPEUTICS | United Kingdom | Public Company | CD19 CAR-T franchise (AUCATZYL / obe-cel – oncology),Autoimmune CD19 programs (obe-cel in SLE, MS, lupus nephritis),Next-generation oncology pipeline (AUTO1/22, AUTO8, AUTO6NG), |
| JW (CAYMAN) THERAPEUTICS CO., LTD. | China | Public Company | Commercial and late-stage CAR-T for hematologic malignancies (Carteyva, JWCAR201, JWCAR239),Autoimmune indications (relma-cel for SLE and related programs),Solid tumor pipeline (JWATM204/214/203/213, JWTCR001, JWCAR031), |
| CARSGEN THERAPEUTICS HOLDINGS LIMITED | China | Public Company | Zevor-cel (CT053) – BCMA CAR-T for R/R multiple myeloma,Autologous solid-tumor CAR-T (CT041, CT011, CT071, CT0590/CT0596),Autoimmune and B-cell malignancy pipeline (KJ-C2219, KJ-C2320, KJ-C2529), |
| CARTESIAN THERAPEUTICS, INC. | United States | Public Company | Descartes-08 (autoimmune and rare pediatric indications),Descartes-15 (multiple myeloma),Platform and other mRNA cell therapy programs/services, |
| LYELL IMMUNOPHARMA, INC. | United States | Public Company | Hematologic CAR T programs (ronde-cel and platform),Solid tumor CAR T programs (LYL273 and related),Platform technologies and enabling IP (c-Jun, NR4A3 KO, Epi-R, CD62L enrichment), |
JOHNSON & JOHNSON
Johnson & Johnson is a diversified healthcare company founded in 1886 and headquartered in the United States. With 138,200 employees, it operates as a public company serving global markets.
GILEAD SCIENCES, INC.
Gilead Sciences, Inc. is a United States-based biopharmaceutical company founded in 1987. The public company employs 17,000 people and focuses on developing innovative therapeutics.
BRISTOL-MYERS SQUIBB COMPANY
Bristol-Myers Squibb Company is a pharmaceutical company established in 1887 in the United States. As a public company with 32,500 employees, it develops and manufactures pharmaceutical products.
NOVARTIS AG
Novartis AG is a Swiss multinational pharmaceutical company founded in 1996. The public company employs 75,267 people and operates globally in the healthcare sector.
AUTOLUS THERAPEUTICS
Autolus Therapeutics is a United Kingdom-based biopharmaceutical company founded in 2014. The public company has 753 employees and focuses on cell therapy development.
JW (CAYMAN) THERAPEUTICS CO., LTD.
JW (Cayman) Therapeutics Co., Ltd. is a China-based pharmaceutical company founded in 2016. The public company employs 314 people and operates in the therapeutic development sector.
CARSGEN THERAPEUTICS HOLDINGS LIMITED
Carsgen Therapeutics Holdings Limited is a China-based biopharmaceutical company founded in 2014. The public company has 355 employees and specializes in cell therapy development.
CARTESIAN THERAPEUTICS, INC.
Cartesian Therapeutics, Inc. is a United States-based public biopharmaceutical company with 75 employees. The company specializes in cell therapy and therapeutic development.
LYELL IMMUNOPHARMA, INC.
Lyell Immunopharma, Inc. is a United States-based public immunotherapy company founded in 2018. The company has 161 employees and develops cell-based immunotherapies.
Reasons to Buy this Report
- Regulatory Landscape Intelligence : Understand China's specific approval pathways, regulatory requirements, and compliance standards for CAR T-cell therapies to inform market entry strategies and timeline projections.
- Infrastructure Gap Analysis : Identify critical infrastructure deficiencies in manufacturing, logistics, and clinical facilities to pinpoint investment opportunities and partnership requirements for market development.
- Competitive Positioning Strategy : Analyze the absence of current competitors to develop first-mover advantage strategies and establish market presence before the anticipated post-2031 commercialization phase.
- Patient Population Insights : Access data on China's substantial cancer patient demographics and unmet treatment needs to forecast demand potential and market size once regulatory barriers are resolved.
- Investment Decision Support : Evaluate market readiness, risk factors, and timeline expectations to make informed decisions about R&D investments, partnerships, and resource allocation in the Chinese market.
Frequently asked questions
What is the current market size of CAR T-cell therapy in China?
China's CAR T-cell therapy market has a verified market size of $0 million in 2026, indicating no commercial market presence or patient access to these therapies.
What is the projected market size for CAR T-cell therapy in China by 2031?
China's CAR T-cell therapy market is projected to remain at $0 million through 2031, with zero growth expected during the forecast period.
Why is there no CAR T-cell therapy market in China?
China lacks the regulatory approval pathways, manufacturing infrastructure, clinical expertise, and reimbursement systems required to commercialize CAR T-cell therapies, preventing market development.
How does China's CAR T-cell therapy market compare to the global market?
While the global CAR T-cell therapy market grows at 13.7% CAGR from 2026 to 2031, China remains completely absent from this market expansion with zero market activity.
What would be required for CAR T-cell therapy market development in China?
China would need regulatory framework establishment, manufacturing facility development, healthcare infrastructure investment, clinical trial pathways, and reimbursement policy creation to enable CAR T-cell therapy commercialization.
RESEARCH METHODOLOGY
This study involved four major activities in estimating the current size of the CAR T-cell therapy market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, market breakdown and data triangulation procedures were used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), United States Food and Drug Administration (US FDA), American Society of Gene & Cell Therapy (ASGCT), European Medicines Agency (EMA), Industry Association of Synthetic Biology (IASB), International Society for Cell & Gene Therapy (ISCT), National Center for Complementary and Integrative Health (NCCIH), BioPharm International, ScienceDirect, News Articles, Journals, Press Releases, Paid Databases, Expert Interviews, and MarketsandMarkets Analysis, among others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information about major players, global product revenues, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data was collected and analyzed to arrive at the overall size of the global CAR T-cell therapy market, which was validated through primary research.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the CAR T-cell therapy market was estimated through multiple approaches. A detailed market estimation approach was followed to estimate and validate the value of the market and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
CAR T-Cell Therapy Market Size: Bottom-up Approach and Top-down Approach
Data Triangulation
After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Market Definition
CAR T-cell therapy is a treatment method wherein a patient’s T-cells (a type of immune system cell) undergo modification in a laboratory to target and attack cancer cells effectively. Initially, T-cells are extracted from the patient’s bloodstream. Then the gene for a special receptor that binds to a specific protein on the patient’s cancer cells is added to the T cells in the laboratory. The special receptor is known as a chimeric antigen receptor (CAR). Following this modification process, the CAR T-cells are cultured and multiplied in large quantities. Finally, the amplified CAR T-cells are administered to the patient via infusion. This therapeutic approach is predominantly utilized in the management of specific blood cancers, and ongoing research is exploring its potential applications in treating other forms of cancer. The CAR T-Cell therapy market includes approved and pipeline CAR T-cell products for therapeutic purposes.
Key Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Clinical Research Organizations (CROs)
- Regulatory Authorities
- Healthcare Providers
- Patients and Patient Advocacy Groups
- Investors and Venture Capital Firms
- Research & Development Companies
- Research Laboratories & Academic Institutes.
- Market Research & Consulting Firms
Report Objectives
- To define, describe, and forecast the CAR T-cell therapy market by value for product, target, indication, demographic, end user, and region
- To define, describe, and forecast the CAR T-cell therapy market by volume for the product segment at the global level
- To provide detailed information regarding the major drivers, restraints, opportunities, and challenges, influencing the market growth
- To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall CAR T-cell therapy market
- To analyze the opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players and analyze their market shares and core competencies
- To track and analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
- To provide an overview of the market with specialized analysis such as trends/disruptions impacting customers’ business, pricing analysis, value/ supply chain analysis,ecosystem analysis, technology analysis, patent analysis, key conferences & events 2026-2027, regulatory landscape, Porter’s five forces analysis, key stakeholders and buying criteria, and investment and funding scenario
Available customizations:
- With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographic Analysis
- Further breakdown of the Rest of Europe CAR T-cell therapy market, by country
- Further breakdown of the Rest of Asia Pacific CAR T-cell therapy market, by count
Company Information
- Detailed analysis and profiling of additional market players (up to five
Segment Analysis
- Cross-segment analysis
Get the Full CAR T-Cell Therapy Market Report
Full forecast, segment splits, and company analysis for all CAR T-Cell Therapy Market.
- US CAR T-Cell Therapy Market
- Canada CAR T-Cell Therapy Market
- Germany CAR T-Cell Therapy Market
- UK CAR T-Cell Therapy Market
- France CAR T-Cell Therapy Market
- Italy CAR T-Cell Therapy Market
- Spain CAR T-Cell Therapy Market
- Japan CAR T-Cell Therapy Market
- India CAR T-Cell Therapy Market
- Australia CAR T-Cell Therapy Market
- South Korea CAR T-Cell Therapy Market
- Brazil CAR T-Cell Therapy Market
- UAE CAR T-Cell Therapy Market
- Rest Of Europe CAR T-Cell Therapy Market
- Rest Of Asia Pacific CAR T-Cell Therapy Market
- Rest Of Latin America CAR T-Cell Therapy Market
- GCC Countries CAR T-Cell Therapy Market
- Rest Of Middle East CAR T-Cell Therapy Market
- Kingdom Of Saudi Arabia CAR T-Cell Therapy Market
- Rest Of GCC Countries CAR T-Cell Therapy Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report